• Patient, age ≥ 18 years, referred for a radiotherapy schedule as described in one of the cohorts.

• WHO performance score 0-3.

• Provision of signed, written and dated IC prior to any study specific procedures.

• Accepted for radiotherapy of the prostate and pelvic lymph node areas.

• Pathology-proven prostate cancer.

• cT1-4

• cN1 on PSMA-PET/CT or pN1 based on node biopsy, SN-procedure or lymph node dissection.

• cM0 on PSMA-PET/CT (except for patients with M1a disease who are still considered for radiotherapy of the prostate and pelvic lymph node areas).

• Accepted for radiotherapy of the cervix (with or without chemotherapy) and pelvic lymph node areas (25 fractions, followed by either a brachytherapy or external radiotherapy boost).

• Pathology-proven cervical cancer.

• FIGO IIA2, IB3 and \> 6cm, IIB-IVA or N+. Or other stage and unfit for surgery.

• cM0 or cM1 and accepted for locoregional radical (chemo)radiation in 25 fractions.

• Accepted for radiotherapy of the bladder, either to the entire bladder or with a boost to the tumor area (with or without chemotherapy).

• Pathology-proven bladder carcinoma.

• cT1-4

• cN0 or cN1-2 after induction treatment (with or without lymph node dissection)

• Accepted for radiotherapy for lung cancer with lymph node metastases (with or without chemotherapy).

• Non-small cell lung cancer (either pathology proven or enough clinical suspicion to warrant radiotherapy to primary tumor and pathologic lymph nodes.

• cT1-4 and cN1-3.

• M0 or m1 and accepted for radical radiotherapy in 24 fractions of 1 or more lymph node metastases and a primary tumor and/or pulmonary metastases.

• Accepted for radiotherapy for head and neck cancer (with or without chemotherapy).

• Pathology-proven carcinoma of the pharynx, oral cavity or larynx.

• cT1-4

• cN0-3 and indication for elective neck radiation (either 1 or 2 sides).

• cM0